


STEM CELL LABORATORY (STCL)



DOCUMENT NUMBER: FLOW-FORM-005

DOCUMENT TITLE:

Immune Reconstitution

DOCUMENT NOTES:

Document Information

Revision: 06

Vault: FLOW-Form-rel

Status: Release

Document Type: FORM

Date Information

Creation Date: 29 Mar 2017

Release Date: 18 Jan 2018

Effective Date: 18 Jan 2018

Expiration Date:

Control Information

Author: MGREESE

Owner: MGREESE

Previous Number: FLOW-FORM-005 Rev 05

Change Number: STCL-CCR-376

Immune Reconstitution Clinical Flow Cytometry Results

Patient:		Hematology Counts from sample		
History #:		WBC/ μ l x 10^3		
Study Date:		% Lymphs		
Days Post Tx:		ALC/ μ l	0	ALC <200. 1 tube only tested.
Reviewed by:				
Date Reviewed:			Note: #DIV/0!	

Results

Basic Lymphocyte Subsets		Other T-cell Subsets of Interest		
Description	Cells/ μ l	Description	% CD3+	
Flow ALC	0	CD45RA+/62L+ (RTE)	0	
CD16/56+ NK cell	0	CD4+	#DIV/0!	
CD19+ B cell	0		% CD4+	
CD3+ T-cell	0	CD45RA+/CD62L+(RTE)	0	
CD4+ T-cell	0	CD25*/CD62L+(T-Reg)	0	
CD8+ T-cell	0	Total CD25**	0	
CD3/16+56 dual pos. "NKT cells"	0		% CD8+	
		CD57*/CD28- ("CTL")	0	
		HLA-DR** ("Activated")	0	
Dendritic Cell Subsets				
Description	Cells/ μ l			
CD123+ ('Lymph')	0.0			
CD11c+ ('Myeloid')	0.0			

*This test was developed and its performance characteristics determined by the Stem Cell Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") as qualified to perform high complexity clinical testing. CLIA# 34D1005310, CAP# 7181142

Normal ranges of Lymphocyte and Dendritic Cell (DC) subsets in the circulation

Absolute (#/ μ l), Relative size (%)

	***2 mos-2 years (mean/90% range)	***2-5 years (mean/90% range)	***5-10 years (mean/90% range)	**Adult (mean \pm 1SD)
Abs CD3 ⁺ T cells	3900 (700-11500)	1900 (850-4300)	1800 (770-4000)	1622 (862-2382)
Abs CD4 ⁺ T cells	2700 (1000-7200)	1100 (500-2700)	1000 (400-2500)	1043 (504-1582)
Abs CD8 ⁺ T cells	1000 (200-5400)	600 (200-1800)	600 (200-1700)	552 (286-818)
Abs CD19 ⁺ B cells	940 (110-7700)	490 (180-1300)	290 (100-800)	288 (109-467)
Abs CD3- / CD16+56 ⁺ NK cells	480 (55-4000)	180 (61-510)	200 (70-590)	290 (104-476)
*Abs CD11c ⁺ 'Myeloid DC'	NA	NA	NA	13 (3.7-23.0)
*Abs CD123c ⁺ 'Lymphoid DC'	NA	NA	NA	8 (3.7-12.3)
%Recent Thymic Emigrant (CD3+ CD4+CD45RA+CD62L+)	74% (40-100)	62% (37-100)	58% (41-81)	40% (25-55)
% CD25 ⁺ T cells	NA	NA	NA	13% (\pm 10.5)
%CD8+/CD57+/CD28- (CTL)	NA	NA	NA	13 (\pm 11.1)
% CD8+/HLA-DR ⁺ T cells	NA	NA	NA	24 (\pm 11)

***Pediatric Abs. T, B, NK cell Reference ranges and % RTE were adopted from E.J.H. Schatorje et al., Scandinavian Journal of Immunology, 2012, 75, 436-444;

*Szabolcs et al. Stem Cells 2003; 21 : 296, **Adult Range (not including DC ranges) established by testing 33 healthy volunteer donors in the Stem Cell Laboratory (~90 test samples); NA : Not Available

Immune Reconstitution Clinical Flow Cyton

Patient:	Patient name	Hemat
History #:	Pt. history number	WBC/ μ l x 10 ³
Study Date:	date of testing	% Lymphs
Days Post Tx:	time point pre or post tx	ALC/ μ l
Reviewed by:	Initial of reviewer	
Date Reviewed:	date of review and entry	Note:

Results

Basic Lymphocyte Subsets		Other
Description	Cells/μl	Description
Flow ALC	autofills after dilution is muliplied	CD45RA+/62L+ (RTE)
CD16/56+ NK cell	autofills after dilution is muliplied	CD4+
CD19+ B cell	autofills after dilution is	
CD3+ T-cell	autofills after dilution is muliplied	CD45RA+/CD62L+(RT E)
CD4+ T-cell	autofills after dilution is muliplied	CD25*+/CD62L+(T-Reg)
CD8+ T-cell	autofills after dilution is muliplied	Total CD25*+
CD3/16+56 dual pos. “NKT cells”	atuofills directly	
		CD57*+/CD28- (“CTL”)
Dendritic Cell Subsets		HLA-DR*+ (“Activated”)
Description	Cells/μl	
CD123+ (‘Lymph’)	autofills directly	
CD11c+ (‘Myeloid’)	autofills directly	

**This test was developed and its performance characteristics determined by the Stem Cell Laboratory. It has not been cleared or approved by the FDA. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") a CLIA# 34D1005310, CAP# 7181142*

Normal ranges of Lymphocyte and Dendritic Cell (DC) subsets
Absolute (#/ μ l), Relative size (%)

	***2 mos-2 years (mean/90% range)	***2-5 years (mean/90% range)
--	--------------------------------------	----------------------------------

Abs CD3 ⁺ T cells	3900	1900
	(700-11500)	(850-4300)
Abs CD4 ⁺ T cells	2700	1100
	(1000-7200)	(500-2700)
Abs CD8 ⁺ T cells	1000	600
	(200-5400)	(200-1800)
Abs CD19 ⁺ B cells	940	490
	(110-7700)	(180-1300)
Abs CD3- / CD16+56 ⁺ NK cells	480	180
	(55-4000)	(61-510)
*Abs CD11c ⁺ 'Myeloid DC'	NA	NA
*Abs CD123c ⁺ 'Lymphoid DC'	NA	NA
%Recent Thymic Emigrant (CD3+ CD4+CD45RA+CD62L+)	74% (40-100)	62% (37-100)
% CD25 ⁺ T cells	NA	NA
%CD8+/CD57+/CD28- (CTL)	NA	NA
% CD8+/HLA-DR ⁺ T cells	NA	NA
***Pediatric Abs. T, B, NK cell Reference ranges and % RTE were adopted from E.J.H. Schatorje et al 444; *Szabolcs et al. Stem Cells 2003; 21 : 296,**Adult Range (not including DC ranges) established by Laboratory (~90 test samples); NA : Not Available		

Test Results**Hematology Counts from sample**hematology analyzer
resulthematology analyzer
result

autofill Full Panel

Enter dilution factor below

autofill

or if sample is diluted, otherwise leave as 1

T-cell Subsets of Interest

% CD3+

Enter % values below

Enter **Cells/μl** below

autofills

from tube 3 analysis

autofills

autofills

#VALUE!

6+56+/CD3 neg absol

% CD4+

% of CD4+

CD19 absolute

autofills

from tube 3 analysis

CD3 absolute

autofills

from tube 4 analysis

CD4 absolute

autofills

from tube 4 analysis

CD8 absolute

% CD8+

% of CD8+

NKT absolute

autofills

from tube 5 analysis

autofills

from tube 5 analysis

Cells/μl

ALCs compared

From tube 8 analysis

From tube 8 analysis

been cleared or approved by the U.S. Food and Drug Administration. It should not be regarded as investigational or for use in clinical testing.

Test Results in the circulation

***5-10 years
(mean/90% range)

**Adult
(mean \pm 1SD)

1800	1622
(770-4000)	(862-2382)
1000	1043
(400-2500)	(504-1582)
600	552
(200-1700)	(286-818)
290	288
(100-800)	(109-467)
200	290
(70-590)	(104-476)
NA	13 (3.7-23.0)
NA	8 (3.7-12.3)
58% (41-81)	40% (25-55)
NA	13% (± 10.5)
NA	13 (± 11.1)
NA	24 (± 11)

., Scandinavian Journal of Immunology,2012,75, 436-
/ testing 33 healthy volunteer donors in the Stem Cell

ALC 1

ALC 2

Tube 2 ALC
or Tube 1
again for 1
tube assay

Tube 1 ALC

ute

Signature Manifest**Document Number:** FLOW-FORM-005**Revision:** 06**Title:** Immune Reconstitution

All dates and times are in Eastern Time.

FLOW-FORM-005 Immune Reconstitution**Author**

Name/Signature	Title	Date	Meaning/Reason
Melissa Reese (MGREESE)		08 Nov 2017, 01:04:29 PM	Approved

Manager

Name/Signature	Title	Date	Meaning/Reason
Barbara Waters-Pick (WATE02)		08 Nov 2017, 07:23:08 PM	Approved

Medical Director

Name/Signature	Title	Date	Meaning/Reason
Joanne Kurtzberg (KURTZ001)		09 Nov 2017, 07:55:16 AM	Approved

Quality

Name/Signature	Title	Date	Meaning/Reason
John Carpenter (JPC27)		09 Nov 2017, 10:47:47 AM	Approved

Document Release

Name/Signature	Title	Date	Meaning/Reason
Sandy Mulligan (MULLI026)		04 Jan 2018, 11:07:02 AM	Approved